Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro

Related Content

Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference
Are Emerging Markets Part Of Big Pharma's Core Business?
Insider Analysis From Datamonitor: Increasing Investment In Emerging Markets Shifts Licensing And Deals Focus To Opportunities In Asia-Pacific
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
Patent Cliff Leads Pfizer To Begin Direct Sales To Pharmacies; Aussie Distributors Reeling
Asia Spotlight: Biocon Chair Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition
As More Indian Companies Dive Into Biosimilars, Will Success In Generic Drugs Repeat?
Pfizer, Biocon Brush Off Deal Talks As Speculative, But Is There Fire Behind The Smoke?



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts